| 摘要: |
| 目的:观察匹多莫德对过敏性紫癜(HSP)患儿CD4+CD25+CD127- 调节性T细胞的影响。方法:选择80例HSP患儿随机分为匹多莫德治疗组和常规治疗组各40例,两组患儿均给予常规治疗,匹多莫德组加用匹多莫德颗粒口服。检测所有患儿治疗前及治疗2周后CD4+CD25+CD127-调节性T细胞比例及血清IL-10、IL-4 及INF-γ水平。结果:治疗后匹多莫德组CD4+CD25+CD127-调节性T细胞比例为(3.85±0.97)%,较常规治疗组(2.54±0.89)% 升高,差异有统计学意义(P<0.01)。治疗后匹多莫德组血清IL﹣10 和IL﹣4 水平为(29.58±8.42) pg/mL、(76.47±16.45) ng/L,较常规治疗组的(40.89±9.67) pg/mL、(96.52±18.79)ng/L 降低,差异均有统计学意义(P均<0.05);匹多莫德组血清INF鄄酌水平为(89.54±15.87)ng/L,较常规治疗组的(77.43±15.32)ng/L 升高,差异有统计学意义(P<0.05);匹多莫德组INF﹣γ/IL﹣4为1.17±0.43,较常规治疗组的0.81±0.32升高,差异有统计学意义(P<0.01)。结论:匹多莫德辅助治疗HSP患儿能提高CD4+CD25+CD127- 调节性T细胞比例,减轻炎症反应,纠正免疫失衡。 |
| 关键词: 匹多莫德 过敏性紫癜 外周血CD4+CD25+CD127- 调节性T细胞 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2018.01.006 |
|
| 基金项目: |
|
| Pidotimod on Peripheral Blood CD4+CD25+CD127- Regulatory T Cells of Children with Henoch-Schönlein Purpura |
| Wei Hongping, Wu Min, Wu Liping |
| (Yiwu Hospital Affiliated Wenzhou Medical University, Zhejiang Yiwu 322000, China) |
| Abstract: |
| Objective: To explore the influence of pidotimod on peripheral blood CD4+CD25+CD127- regulatory T cells in children with Henoch﹣Schönlein purpura (HSP). Methods: Eighty cases of HSP were selected and randomly divided into the treatment group and the control group, 40 cases in each group. The control group was given the routine therapy, while the treatment group was added oral pidotimod granules on the basis of the routine therapy. The proportion of peripheral blood CD4+CD25+CD127- regulatory T cells and the serum of IL﹣10, IL﹣4 and INF﹣γ levels were tested before and after 2 weeks' treatment. Results: The proportion of CD4+CD25+CD127- regulatory T cells in the treatment group was 3.85%±0.97%, which was significantly higher than the control group (2.54%±0.89%) after treatment (P<0.01). The serum levels of IL﹣10 and IL﹣4 in the treatment group were (29.58±8.42) pg/mL and (76.47±16.45) ng/L, which were significantly lower than the control group ((40.89±9.67) pg/mL and (96.52±18.79) ng/L) after treatment (all P<0.05). The serum level of INF﹣γ in the treatment group was (89.54±15.87) ng/L, which was significantly higher than the control grou ((77.43±15.32) ng/L) after treatment (P<0.05). The INF﹣±/IL﹣4 in the treatment group (1.17±0.43) was significantly higher than the control group (0.81±0.32) after treatment (P<0.01). Conclusion: Pidotimod can increase the proportions of CD4+CD25+CD127- regulatory T cells in the onset of HSP in children. It can relieve the inflammatory reaction and correct immune imbalance. |
| Key words: pidotimod Henoch-Sch?nlein purpura peripheral blood CD4+CD25+CD127- regulatory T cells |
